Publications 2017

1. Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I, Beltrame L, Hato SV, Ellebaek E, Gross S, Nguyen VA, Weinlich G, Ragoussis J, Baban D, Schuler-Thurner B, Svane IM, Romani N, Austyn JM, De Vries IJM, Schuler G, Cavalieri D, Figdor CG. Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. Oncotarget, 2017. 8(40): 67439-56.

2. Hammink R, Eggermont LJ, Zisis T, Tel J, Figdor CG, Rowan AE, Blank KG. Affinity-Based Purification of Polyisocyanopeptide Bioconjugates. Bioconjug Chem, 2017. 28(10): 2560-8.

3. Robin M, Porcher R, Ciceri F, van Lint MT, Santarone S, Ehninger G, Blaise D, Gullbas Z, Gonzales Muniz S, Michallet M, Velardi A, Koster L, Maertens J, Sierra J, Selleslag D, Radujkovic A, Diez-Martin JL, Kanz L, Arroyo CH, Niederwieser D, Huang H, McDonald A, de Witte T, Koc Y, Kroger N. Haploidentical transplant in patients with myelodysplastic syndrome. Blood Adv, 2017. 1(22): 1876-83.

4. Otrock ZK, Hock KG, Riley SB, de Witte T, Eby CS, Scott MG. Elevated serum ferritin is not specific for hemophagocytic lymphohistiocytosis. Ann Hematol, 2017. 96(10): 1667-72.

5. Schmid C, de Wreede LC, van Biezen A, Finke J, Ehninger G, Ganser A, Volin L, Niederwieser D, Beelen D, Alessandrino P, Kanz L, Schleuning M, Passweg J, Veelken H, Maertens J, Cornelissen JJ, Blaise D, Gramatzki M, Milpied N, Yakub-Agha I, Mufti G, Rovira M, Arnold R, De Witte T, Robin M, Kroger N. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia after allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of European Society of Blood and Marrow Transplantation. Haematologica, 2017.

6. Scheid C, de Wreede L, van Biezen A, Koenecke C, Gohring G, Volin L, Maertens J, Finke J, Passweg J, Beelen D, Cornelissen JJ, Itala-Remes M, Chevallier P, Russell N, Petersen E, Milpied N, Richard Espiga C, Peniket A, Sierra J, Mufti G, Crawley C, Veelken JH, Ljungman P, Cahn JY, Alessandrino EP, de Witte T, Robin M, Kroger N. Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party. Bone Marrow Transplant, 2017. 52(11): 1519-25.

7. van der Woude LL, Gorris MAJ, Halilovic A, Figdor CG, de Vries IJM. Migrating into the Tumor: a Roadmap for T Cells. Trends Cancer, 2017. 3(11): 797-808.

8. Zuidscherwoude M, Dunlock VE, van den Bogaart G, van Deventer SJ, van der Schaaf A, van Oostrum J, Goedhart J, In 't Hout J, Hammerling GJ, Tanaka S, Nadler A, Schultz C, Wright MD, Adjobo-Hermans MJW, van Spriel AB. Tetraspanin microdomains control localized protein kinase C signaling in B cells. Sci Signal, 2017. 10(478): eaag2755.

9. Hammink R, Mandal S, Eggermont LJ, Nooteboom M, Willems PH, Tel J, Rowan AE, Figdor CG, Blank KG. Controlling T-Cell Activation with Synthetic Dendritic Cells Using the Multivalency Effect. ACS Omega, 2017. 2(3): 937-45.

10. de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kroger N. Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. Blood, 2017. 129(13): 1753-62.

11. Mathan TSM, Textor J, Skold AE, Reinieren-Beeren I, van Oorschot T, Bruning M, Figdor CG, Buschow SI, Bakdash G, de Vries IJM. Harnessing RNA sequencing for global, unbiased evaluation of two new adjuvants for dendritic-cell immunotherapy. Oncotarget, 2017. 8(12): 19879-93.

12. Ruutu T, Gratwohl A, Niederwieser D, de Witte T, van der Werf S, van Biezen A, Mohty M, Kroger N, Rambaldi A, McGrath E, Sureda A, Basak G, Greinix H, Duarte RF. The EBMT-ELN working group recommendations on the prophylaxis and treatment of GvHD: a change-control analysis. Bone Marrow Transplant, 2017. 52(3): 357-62.

13. Garelius HK, Johnston WT, Smith AG, Park S, de Swart L, Fenaux P, Symeonidis A, Sanz G, Cermak J, Stauder R, Malcovati L, Mittelman M, van de Loosdrecht AA, van Marrewijk CJ, Bowen D, Crouch S, de Witte TJ, Hellstrom-Lindberg E. Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome. J Intern Med, 2017. 281(3): 284-99.

14. Cruz LJ, Tacken PJ, Eich C, Rueda F, Torensma R, Figdor CG. Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity. Nanomedicine (Lond), 2017. 12(5): 491-510.

15. Vasaturo A, Di Blasio S, Verweij D, Blokx WA, van Krieken JH, de Vries IJ, Figdor CG. Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. Histopathology, 2017. 70(4): 643-9.

16. van Deventer SJ, Dunlock VE, van Spriel AB. Molecular interactions shaping the tetraspanin web. Biochem Soc Trans, 2017. 45(3): 741-50.

17. de Winde CM, Elfrink S, van Spriel AB. Novel Insights into Membrane Targeting of B Cell Lymphoma. Trends Cancer, 2017. 3(6): 442-53.

18. Te Riet J, Joosten B, Reinieren-Beeren I, Figdor CG, Cambi A. N-glycan mediated adhesion strengthening during pathogen-receptor binding revealed by cell-cell force spectroscopy. Sci Rep, 2017. 7(1): 6713.

19. Qiu LP, Wimmers F, Weiden J, Heus HA, Tel J, Figdor CG. A membrane-anchored aptamer sensor for probing IFN gamma secretion by single cells. Chemical Communications, 2017. 53(57): 8066-9.

20. Kroger N, Iacobelli S, Franke GN, Platzbecker U, Uddin R, Hubel K, Scheid C, Weber T, Robin M, Stelljes M, Afanasyev B, Heim D, Deliliers GL, Onida F, Dreger P, Pini M, Guidi S, Volin L, Gunther A, Bethge W, Poire X, Kobbe G, van Os M, Brand R, de Witte T. Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial). J Clin Oncol, 2017. 35(19): 2157-64.

21. de Swart L, Smith A, MacKenzie M, Symeonidis A, Neukirchen J, Mikulenkova D, Vallespi T, Zini G, Paszkowska-Kowalewska M, Kruger A, Saft L, Fenaux P, Bowen D, Hellstrom-Lindberg E, Cermak J, Stauder R, Tatic A, Holm MS, Malcovati L, Madry K, Droste J, Blijlevens N, de Witte T, Germing U. Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance. Ann Hematol, 2017. 96(7): 1105-12.

22. Cook G, Iacobelli S, van Biezen A, Ziagkos D, LeBlond V, Abraham J, McQuaker G, Schoenland S, Rambaldi A, Halaburda K, Rovira M, Sica S, Byrne J, Sanz RG, Nagler A, van de Donk NW, Sinisalo M, Cook M, Kroger N, De Witte T, Morris C, Garderet L. High-dose therapy and autologous stem cell transplantation in patients with POEMS syndrome: a retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancy Working Party of the European Society for Blood & Marrow Transplantation. Haematologica, 2017. 102(1): 160-7.

23. Heidenreich S, Ziagkos D, de Wreede LC, van Biezen A, Finke J, Platzbecker U, Niederwieser D, Einsele H, Bethge W, Schleuning M, Beelen DW, Tischer J, Nagler A, Glass B, Maertens J, Yanez L, Beguin Y, Sill H, Scheid C, Stelljes M, Ganser A, Zachee P, Selleslag D, de Witte T, Robin M, Kroger N. Allogeneic Stem Cell Transplantation for Patients Age >/= 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT. Biol Blood Marrow Transplant, 2017. 23(1): 44-52.

24. Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant, 2017. 52(2): 209-15.

25. Selleslag D, Suciu S, Meloni G, Muus P, Halkes CJ, Venditti A, Ramadan SM, Pruijt H, Meert L, Vignetti M, Marie JP, Wittnebel S, de Witte T, Amadori S, Willemze R, Baron F. Low-dose clofarabine in combination with a standard remission induction in patients aged 18-60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial. Haematologica, 2017. 102(2): e47-e51.

26. Weiden J, Tel J, Figdor CG. Synthetic immune niches for cancer immunotherapy. Nat Rev Immunol, 2017.

27. Hato SV, Figdor CG, Takahashi S, Pen AE, Halilovic A, Bol KF, Vasaturo A, Inoue Y, de Haas N, Verweij D, Van Herpen CML, Kaanders JH, van Krieken J, Van Laarhoven HWM, Hooijer GKJ, Punt CJA, Asai A, de Vries IJM, Joost Lesterhuis W. Direct inhibition of STAT signaling by platinum drugs contributes to their anti-cancer activity. Oncotarget, 2017. 8(33): 54434-43.

28. Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Dohner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Dohner H. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med, 2017. 377(5): 454-64.

29. Martino R, Henseler A, van Lint M, Schaap N, Finke J, Beelen D, Vigouroux S, Alessandrino EP, Mufti GJ, Veelken JH, Bruno B, Yakoub-Agha I, Volin L, Maertens J, Or R, Leblond V, Rovira M, Kalhs P, Alvarez AF, Vitek A, Sierra J, Wagner E, Robin M, de Witte T, Kroger N. Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes. Bone Marrow Transplant, 2017. 52(8): 1107-12.

30. da Silva-Coelho P, Kroeze LI, Yoshida K, Koorenhof-Scheele TN, Knops R, van de Locht LT, de Graaf AO, Massop M, Sandmann S, Dugas M, Stevens-Kroef MJ, Cermak J, Shiraishi Y, Chiba K, Tanaka H, Miyano S, de Witte T, Blijlevens NMA, Muus P, Huls G, van der Reijden BA, Ogawa S, Jansen JH. Clonal evolution in myelodysplastic syndromes. Nat Commun, 2017. 8: 15099.

31. Bull C, Collado-Camps E, Kers-Rebel ED, Heise T, Sondergaard JN, den Brok MH, Schulte BM, Boltje TJ, Adema GJ. Metabolic sialic acid blockade lowers the activation threshold of moDCs for TLR stimulation. Immunol Cell Biol, 2017. 95(4): 408-15.

32. Zuidscherwoude M, Worah K, van der Schaaf A, Buschow SI, van Spriel AB. Differential expression of tetraspanin superfamily members in dendritic cell subsets. PLoS One, 2017. 12(9): e0184317.

33. Hoogstad-van Evert JS, Cany J, van den Brand D, Oudenampsen M, Brock R, Torensma R, Bekkers RL, Jansen JH, Massuger LF, Dolstra H. Umbilical cord blood CD34+ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD/SCID/IL2Rgnull mice. Oncoimmunology, 2017. 6(8): e1320630.